WASHINGTON, Feb. 1, 2017 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) issued thefollowing statement on a new report by a splinter group of oncologists attacking the use of direct and indirect remuneration (DIR) in the popular Medicare Part D program:
"Today's attack on Medicare Part D plans' tools to reduce drug costs is
DIR reduces premiums for Medicare Part D beneficiaries, which leads to lower costs for the federal government. Stable and affordable premiums contribute to a 90% satisfaction rate among Part D enrollees for their drug plan.
Furthermore, the paper's dubious claim that DIR in Part D contribute to higher drug prices raises an obvious question: why are drug prices so high in Medicare Part B?
In reality, Part D plans reduce costs not only by negotiating price concessions on brand and generic drugs, but also by lowering premiums, which reduces costs for all Medicare beneficiaries as well as U.S. taxpayers."
PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pcma-refutes-report-from-oncologist-splinter-group-on-medicare-part-d-300400538.html
SOURCE Pharmaceutical Care Management Association
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All